New Treatment for IDH mt Gliomas
Release Date:
Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. Read the related article in The New England Journal of Medicine. Visit NPUb.org/Podcast for associated article links.
New Treatment for IDH mt Gliomas